Targeted Genomic Integration for Stable Recombinant Protein Expression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Traditional cell line engineering methods for recombinant therapeutic protein expression result in unstable and diverse clonal populations due to random integration of transgenes, leading to inconsistent expression levels and protein heterogeneity.

Innovation Solution

Site-specific targeted integration of exogenous sequences into predefined genomic loci, such as the regions bp 1,090,000 to bp 1,127,000 of NCBI Reference Sequence NW_003613934.1, using targeting endonucleases and donor polynucleotides to ensure stable and predictable expression without affecting cellular function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If random integration of transgenes is used, then cell lines can be developed for recombinant therapeutic protein expression, but the cell lines become unstable and show marked diversity in expression level and protein heterogeneity

Engineering Contradiction:
Improverecombinant therapeutic protein expressionVSAvoidclonal population stability
Core Design Contradiction:
ProductivityVSStability of the object's composition

Solution Approach 1:

The patent segments the genome into specific targetable loci with defined boundaries (e.g., attP sites, loxP sites, FRT sites). By dividing the genome into discrete integration regions with specific recognition sequences, the patent enables controlled integration at predetermined locations rather than random integration, thereby achieving both high expression and clonal stability.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent uses site-specific recombinases (Cre, Flp, Bxb1, etc.) as intermediary enzymes that mediate the integration of exogenous sequences into specific genomic loci. These recombinases recognize specific DNA sequences and catalyze precise recombination events, serving as intermediaries between the transgene and the genome to achieve stable, targeted integration without random insertion.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If site-specific targeted integration is used, then stable and predictable expression is achieved, but suitable genomic locations must be identified and verified

Engineering Contradiction:
Improveexpression predictabilityVSAvoidgenomic site identification process
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent performs preliminary identification and characterization of suitable genomic integration sites before actual transgene integration. Specific loci are pre-selected based on criteria such as being in genomic regions that support high expression, having available flanking sequences for recombinase recognition, and not disrupting essential cellular genes. This preliminary preparation simplifies subsequent integration processes.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent develops universal genomic loci that can accept multiple different transgenes and expression cassettes through the same recombinase recognition sites. These universal integration sites serve multiple functions: they can integrate various therapeutic proteins, accommodate different selectable markers, and work with multiple recombinase systems, thereby reducing the need to identify separate sites for each integration event.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Productivity

If multiple exogenous sequences are integrated into the genome, then protein expression can be enhanced, but integration into non-functional regions may cause gene silencing or position effects

Engineering Contradiction:
Improveprotein expression levelVSAvoidgene silencing and position effects
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent integrates exogenous sequences into specific local genomic regions that have been characterized to support high, stable expression without silencing. These localized integration sites are selected for their favorable chromatin environment, appropriate histone modifications, and distance from heterochromatic regions. By controlling the local quality of the integration site, the patent enhances expression while avoiding position effects.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent uses site-specific recombinases to convert the potential harm of random integration into the benefit of precise, controlled integration. The recombinase system, which could otherwise cause unwanted genomic rearrangements, is instead harnessed to achieve accurate insertion at predetermined safe harbor loci, transforming a source of instability into a tool for reliable, reproducible integration.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentEP3956460B1Stable targeted integration
Publication Date: 2026.02.11 EMD MILLIPORE CORP
  • EP3956460B1 patent drawingFigure 1A
  • EP3956460B1 patent drawingFigure 1B
  • EP3956460B1 patent drawingFigure 2

AI summary

Methods for integrating exogenous sequences in genomic loci, wherein the integration is stable and the exogenous sequence can function predictably and reliably.